E Rickshaw Manufacturers in India – Pioneering the Future of Electric Mobility
India’s shift toward sustainable and...
Alentis Therapeutics Secures $181M to Advance Targeted Therapies for Solid Tumors
Alentis Therapeutics Secures $181M to Advance Targeted Therapies for Solid TumorsAlentis Therapeutics, a leading biopharmaceutical company developing targeted treatments for cancer and fibrotic diseases, has secured $181.4 million in Series D funding round to develop targeted therapies for solid tumors. The financing round was spearheaded by OrbiMed, Novo Holdings and Jeito Capital, with significant contributions from new investors Longitude Capital, Frazier Life Sciences, Catalio Capital, Avego Bioscience Capital, and Piper Heartland Healthcare Capital.
Please login to comment on this Post